Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DEJ a reply from management posted on MB
The funds will be used for the 2014 Woodrush development program and we anticipate a significant ramp of production as per our corporate presentation. We utilized institutional investors in order to move forward without encumbering additional debt. The discount for the transaction was calculated based on vwap (volume weighted average price) over a period of time
MDXH Signs Two New Insurance Agreements Providing Increased Access to ConfirmMDx for Prostate Cancer
Agreements add more than 4.5 million insured lives
IRVINE, CA, and HERSTAL, BELGIUM - August 14, 2014 MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed agreements with Ancillary Care Services (ACS), a subsidiary of American CareSource Holdings Inc. and separately, Consilium, LLC. ACS offers its providers quality and cost-effective healthcare services through their managed care network agreements covering 4.5 million lives. Consilium is a complete solution provider for out-of-network healthcare claims. The agreements provide patients access to MDxHealth's ConfirmMDx® for Prostate Cancer test.
The addition of these agreements to MDxHealth's current contracted network raises coverage access to the ConfirmMDx for Prostate Cancer testing to over 152 million covered lives throughout the U.S. MDxHealth continues to ensure coverage and reimbursement contracting with PPO, commercial payors and other specialized networks. These agreements permit successful claims adjudication and payment for the ConfirmMDx for Prostate Cancer test for insured patients.
DEJ I agree about the timing but it's also how people react to it. Most probably don't even understand the offering. The stock needs to go to 0.35 for the instuts. So after the panic sellers are gone it is my belief that the pps will go back up.
And goodmorning to you and all!
I am betting on MDXH (Belgian company) who's biomarker is used by EXAS and have high hopes that MDXH shareprice will benefit largely. It is said that royalties will be mid digits' i am waiting for the exact number but 4%, 5% or 6% on 1 billion Dollar adds up.
Good luck!
MDxHealth (R) : MDxHealth Licensee Exact Sciences Receives FDA Approval for its Cologuard Colon Cancer Screening Assay
The Centers for Medicare & Medicaid Services issues a preliminary decision to cover the cost of the test
IRVINE, CA, and HERSTAL, BELGIUM - August 12, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the U.S. Food and Drug Administration's (FDA) has approved Exact Sciences' Cologuard® stool-DNA-based, non-invasive colorectal cancer screening test. The test incorporates one of MDxHealth's epigenetic biomarkers, which was licensed Upon product launch, anticipated before the end of 2014, MDxHealth expects to receive milestone payments and royalties from the sale of the test under the terms of its licensing agreement.
mdxhealth.com/news-and-events/press-r...
EXAS yesss received FDA approval
FDA approves first non-invasive DNA screening test for colorectal cancer
Collaboration with CMS contributed to proposed Medicare
“This is the first time in history that FDA has approved a technology and CMS has proposed national coverage on the same day,” said Patrick Conway, chief medical officer and deputy administrator for innovation and quality for CMS. “This parallel review represents unprecedented collaboration between the two agencies and industry and most importantly will provide timely access for Medicare beneficiaries to an innovative screening test to help in the early detection of colorectal cancer.”
MSTX yes that is very good.
DEJ there are 3 instuts that will want to make money just like we do. They will receive shares at 0.25 AND have the right to purchase shares at 0.35 before Dec '15. They wouldn't have agreed to this if they didn't think the price will go up to at least 0.35. And once they have these shares, they will sell those much higher. So imo the good (drilling, developing more wells, growing production) outweighs the small dilution.
Be prepared to swingtrade and follow the(ir) money!
Apologies. Server has hick ups
DEJ perfect close! On our way to at least a double.
Keep drilling!
DEJ perfect close! On our way to at least a double.
Keep drilling!
DEJ perfect close! On our way to at least a double.
Keep drilling!
DEJ perfect close! On our way to at least a double.
Keep drilling!
DEJ 0.3299 she's a real tease lol
DEJ I aaaaam! almost blue skies above....
DEJ patiently waiting on a break of 0.33
DEJ patiently waiting on a break of 0.33
Some twitter group picked it up at 1.01 I just noticed.
DEJ They are reporting 561 BOE/d to achieve $730K net. Their guidance is to be over 1000 (1400) BOE/d by the end of the year.
That should push the pps much higher. I will be patient and try not to sell too early ;)
DEJ gapping. Love!
DEJ went from a quarterly loss of -$1.1m to $700k in net is remarkable.
In Q1, the company reported a loan of $3.5million, of which they borrowed $600k to stay in operation. In Q2, they paid off this debt.
They addressed the "going concern" statements.
I would expect a steady rise in share price. (I hope) :)
DEJ went from a quarterly loss of -$1.1m to $700k in net is remarkable.
In Q1, the company reported a loan of $3.5million, of which they borrowed $600k to stay in operation. In Q2, they paid off this debt.
They addressed the "going concern" statements.
I would expect a steady rise in share price. (I hope) :)
DEJ $730,000 Net Income for Q2 2014
33% Increase in Daily Production, 56% Reduction in Secured Debt
Other Key Financial and Operating Highlights are:
Refinanced the Kokopelli project in Colorado by creating a joint venture involving the transfer of 65% of the Company’s working interest in the initial 4 wells drilled in 2013, together with certain related production facilities, for $4,136,000 (US$3,876,000) cash;
Retaining a 25% working interest in the Kokopelli project and being carried for 25% of the next US$16.0 million in project development expenditures planned for 2014;
Reduced G&A per BOE by 31% from $22.19/boe for the three months ended June 30, 2013 to $15.24/BOE for the current quarter;
Repaid $3.5 million in secured debt;
Removed, with the concurrence of the Company’s auditors, all “going concern risk” references in the Company’s unaudited financial statements and related Management’s Discussion & Analysis for the three and six months ended June 30, 2014.
DEJ an independent oil and gas exploration and production company operating in North America’s Piceance Basin and Peace River Arch regions, today announced its financial results for the three and six month periods ended June 30, 2014. The Company generated net income of $730,000 for the three months ended June 30, 2014 compared with a loss of $1.1 million in Q2 2013 and increased production by 33% to an average of 561 boe/d for the three months ended June 30, 2014 compared with 422 boe/d in Q2 2013.
DEJ 0.30 + 11,42 % very nice recovery from last weeks drop
DEJ at 0.268 is far too cheap!
After reading the Q3 corporate presentation I am going to hold DEJ for much much longer. 546 BOE production right now plus 300 BOE to add this year from wooddrush plus 500 BOE from koko = 1,346 BOE production before year end.
KoKopelli current:
4 Wells in Production since Q3 2013
2014: 8-12 new WF wells in 2014 Production by December 2014
2015: 8-16 WF/ Mancos wells
Woodrush:
3 Oil wells and 8 Natural Gas wells
2014: 2 new wells to be drilled in H2 2014 Production by November 2014
- $20MM Joint Venture at Kokopelli closed on June 30, 2014
- US debt eliminated, balance sheet much improved
SeeThruEquity- Initial Target: US $0.66
Zacks- Current Target: US $0.51
Casimir Capital- Initial Target: US $0.50
These targets are very conservative imo.
Yes and some cost even more.... but wearing Loubies makes a woman instantly more intriguing and sexy!
Yes and some cost even more.... but wearing Loubies makes a woman instantly more intriguing and sexy!
Hmmm tripple that amount but hey I am worth it lol ;)
DEJ good. I can wait for more gains.
Yes, Christian Louboutin the sexiest shoes with their iconic red soles ;)
DEJ I had hoped she would continue today
DEJ I was shopping all day y'day...treating myself on a new Chanel bag and a pair of Louboutin...what makes a girl more happy? To come back home and see that DEJ had also a very nice day :)
DEJ may finally start going higher. The clarification report is showing how well they are doing.
DEJ CLARIFICATION of Dejour Reports 44% Increase in Daily Production in Q1 2014, 37% Increase in Gross Revenues, & 283% Increase ...
http://finance.yahoo.com/news/clarification-non-gaap-measures-2013-210500901.html
DEJ CLARIFICATION of Dejour Reports 44% Increase in Daily Production in Q1 2014, 37% Increase in Gross Revenues, & 283% Increase ...
http://finance.yahoo.com/news/clarification-non-gaap-measures-2013-210500901.html
MSTX CEO blog
Dear Friends,
The second quarter of 2014 was a busy time for Mast. Most importantly, we focused on enrolling patients in our pivotal phase 3 study of MST-188 in sickle cell disease (SCD) and advanced many other initiatives to support MST-188 in sickle cell disease.
For example, we reported data from an ex vivo study further supporting MST-188 for SCD and announced the initiation of a sub-study within our phase 3 EPIC study to measure the effects of MST-188 on tissue oxygenation. I’m also pleased to share that the EPIC study’s Drug Safety and Monitoring Board (DSMB) held its first scheduled data review meeting and, based on data from the first cohort of subjects enrolled in EPIC, it recommended that the study proceed without any changes to the protocol. From progress like this, we continue to believe Mast is well-positioned to develop MST-188 as the first drug approved to treat an ongoing vaso-occlusive crisis in patients with sickle cell disease.
Many people are unaware that MST-188 is the most clinically-advanced new drug in development for SCD. But as such, we have the honor of leading a growing and important field, which unfortunately has historically suffered from too little awareness or investment. Remarkably, there has been only one FDA-approved drug for SCD and that approval came a whopping 16 years ago. Surely, patients deserve better. And clearly, the industry can do better. So, in addition to seeking approval for MST-188 in SCD, we support SCD community programs such as the Sickle Cell Disease Foundation of California’s Inspiring Dreams Walk-A-Thon and Camp Crescent Moon and the Foundation for Sickle Cell Research’s 8th Annual Sickle Cell Disease Research and Educational Symposium. Additionally, a free mobile app we developed for patients, VOICE Crisis Alert™, now has over 900 downloads.
We also created and again will host the 3rd Annual Sickle Cell Disease Therapeutics Conference in New York City on September 15th. This event serves as a forum to raise awareness for SCD among the investment community. This year, conference participants will hear presentations from members of the U.S. Food and Drug Administration, the Centers for Disease Control and the Sickle Cell Disease Association of America. In addition, clinical-stage companies (both public and private), leading physicians, patients, and healthcare analysts will discuss key issues and emerging trends in SCD.
With regard to our other pipeline programs, we’ve made significant progress with the development of MST-188 in acute limb ischemia (ALI), an indication for which we were granted orphan drug status by the FDA late last year. We initiated our phase 2 study of MST-188 in combination with rt-PA earlier this year. And, as planned, we submitted our application for orphan drug designation of MST-188 for the treatment of ALI in the European Union during the second quarter.
Furthermore, we recently initiated a nonclinical study of MST-188 in an experimental model of thrombotic stroke to evaluate MST-188’s potential to improve the therapeutic effect of rt-PA and expand the window in which it is effective. If MST-188 increases the therapeutic benefits of rt-PA in this nonclinical model and our phase 2 study in ALI demonstrates that MST-188 in combination with rt-PA accelerates time-to-reperfusion, we believe there will be interest from potential partners to develop MST-188 in stroke, a major market opportunity.
For the phase 2 asset we obtained via the acquisition of Aires Pharmaceuticals earlier this year, we recently locked the database for 20 patients who completed treatment in Aires’ phase 2 study in patients with pulmonary arterial hypertension. We anticipate announcing data from this trial in the third quarter of 2014. This data, along with ongoing discussions with experts in pulmonary hypertension and heart failure, will help us determine the optimal development strategy for AIR001, which we also expect to announce in Q3.
Finally, we announced last month the appointment of Howard C. Dittrich, M.D., F.A.C.C., to our Board of Directors. Dr. Dittrich, a cardiologist by training, has more than 20 years of experience in cardiac therapeutic research and clinical development. His medical training and extensive clinical development and regulatory affairs experience, particularly with cardiovascular agents, is highly relevant to our development programs and brings a wealth of development experience to our team.
Our 24 employees are proud of the progress we’ve made, and as always, I look forward to keeping you informed here and through our social media outlets, including Twitter (@MastThera) and Facebook.
U.S. Geothermal is Building Up Steam Again (HTM)
Back on March 26th, yours truly took something of a big risk by penning some bearish thoughts on U.S. Geothermal Inc. (NYSEMKT:HTM). It was nothing personal against the company. It was simply that HTM had gotten overextended.
The premise, of course, was unpopular at the time. U.S. Geothermal Inc. was still basking in the glory of some serious fiscal success, and its outlook was quite encouraging to boot. HTM shares were vulnerable, however, simply because they had taken on a life of their own and were pushed beyond a reasonable price in the wake of the euphoria.
It was, by the way, the right call. HTM shares ended up making a major peak at $1.08 that day, and had fallen to a low of $0.51 by late May.
This reporter isn't revisiting U.S. Geothermal Inc. to gloat, however (well, not to gloat much). HTM is back in focus today as a follow-up on the call, and to post a new near-term bullish call on this geothermal energy name. It looks like the bottom has already been made, and this week's bullish second wind is on the verge of catapulting shares again.
The key to any bullishness from here is actually rooted in what happened back on May 22nd. That multi-month low was just a brush of the key 200-day moving average line (green), and poof - the bulls took over again. The effort didn't last very long; the stock was slumping again by late June. Over the course of the first half of July, however, U.S. Geothermal shares have logged some higher lows while also putting some serious pressure on a ceiling at $0.66. That's where the stock's topped a few times since late May, and it's also roughly where the 100-day moving average line (gray) is; other moving average lines aren't too far away. It's also worth noting the volume on the way up this month so far has been higher than average.
The safe move here would be waiting for HTM to clear $0.66. That may be an unnecessary caution, however. All the tell-tale signs of another rally are already in place, and waiting for the breakout may leave you chasing the stock once it takes flight.
HTM very nice update and it seems that they want to expand